NCT00607425

Terminated

Saliva mRNA Expression Profiling for Early Stage Non-Small C...

Scottsdale Healthcare Source

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

2007-094

Secondary identifiers

IASLC

Study Type

observational

Actual enrollment (reported)

40

Locations

0 countries

Sites

N/A

Timeline

Study Start

August 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

July 2008

Actual (reported)

Study Completion

July 2008

Actual (reported)

Brief Summary

This is a pilot study to test the feasibility of using gene expression from saliva to identify patients with early-stage non-small cell lung cancer (NSCLC). The primary objective of this study is to compare gene expression profiles from saliva from healthy controls and patients with early-stage non-small cell lung cancer. To be eligible, patients with non-small cell lung cancer, must not yet have received treatment for their cancer (surgical removal, chemotherapy, or radiation therapy). Health control participants may participate if they meet eligibility criteria listed below. Eligible enrollees will be asked to submit a one time saliva sample and complete a study questionaire.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Actual enrollment (reported): 40 participants
Study completion date: July 2008
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 2007
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
January 22, 2008
Actual (reported)
First Posted
February 5, 2008
Actual (reported)
Primary Completion
July 2008
Actual (reported)
Study Completion
July 2008
Actual (reported)

Last Updated: July 17, 2008
Status Verified: July 2008
Last Update Submitted: July 15, 2008

Conditions

Non-Small Cell Lung Cancer

Keywords

non-small cell lung cancerscreeningsalivagene expressionhealthy control subject

Study Arms (2)

1

Non-small cell lung cancer patients

2

Healthy control subjects

Eligibility Criteria

Age40 Years - 79 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Untreated, clinical stage I and II non-small cell lung cancer (NSCLC) patients and matching healthy control subjects will be recruited to participate in this study. Untreated patients have not yet had either complete surgical removal of their lung cancer, any chemotherapy, or any radiation therapy to treat their lung cancer.

You may qualify if:

Patients with untreated stage I-II NSCLC OR Healthy control subjects: with a \> 20 pack year history of cigarette smoking OR Never smokers (defined as less than 100 cigarettes over subject's lifetime)

Sponsors & Collaborators

Scottsdale Healthcare
Otherlead
US Department of Veterans Affairs
US federal agencycollaborator
University of Kansas

Biospecimen

Retention: SAMPLES WITH DNA

Saliva

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

Glen J Weiss, MD
TGen Clinical Research Services at Scottsdale Healthcare
PRINCIPAL INVESTIGATOR

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Sponsor Type: OTHER

Study Record Dates

First Submitted

January 22, 2008

First Posted

February 5, 2008

Study Start

August 2007

Date type not reported

This date has not been verified as actual or estimated.

NCT00614822

Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer

Phase 2Completed

NCT00531401

Study of Salirasib to Treat Non-Small Cell Lung Cancer

Phase 2Completed

NCT00686959

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

Phase 3Completed

NCT00380718

Chemotherapy for Patients With Non-Small Cell Lung Cancer

Phase 4Completed

NCT00380666

The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer

Not ApplicableWithdrawn

NCT00420732

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Phase 2Terminated

The investigators recognize that pathologic confirmation is not always available prior to surgical resection of a lung mass. To account for this, subjects with a suspicious lung mass concerning for lung cancer, can be enrolled on this trial, and submit a saliva sample prior to surgical resection (ideally within 45 days of planned surgery).

Adults age 40-79

Ability to understand the investigational nature of the study and sign the informed consent in accordance with institutional and FDA guidelines

You may not qualify if:

No active pulmonary infection, i.e. bronchitis or pneumonia for 6 months
No use of steroid inhalers for \> 6 months
No other prior malignancy is allowed except for adequately treated basal or squamous cell skin cancer, in situ cervical cancer, or other cancers from which the patient has been disease-free for 5 years

Contact the study team to confirm eligibility.

Othercollaborator

University of Colorado, Denver

Othercollaborator

University of California, Los Angeles

Othercollaborator

Primary Completion

July 2008

Actual (reported)

Study Completion

July 2008

Actual (reported)

Last Updated

July 17, 2008

Record last verified: 2008-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00607425
Data provider: ClinicalTrials.gov
Source updated: 2008-07-17
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:55 UTC

Study Stopped

Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Study Arms (2)

1

2

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Study Arms (2)

1

2

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record